TLN468 changes the pattern of tRNA used to read through premature termination codons in CFTR
Journal of Cystic Fibrosis · 2024-11 · 23 (6) · 1185-1194
DOI: 10.1016/j.jcf.2024.07.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024-11. Verfasst von Sabrina Karri und 11 weiteren Autor:innen. Beteiligte Einrichtung: CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, Gif-sur-Yvette, 91198, France. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Codon, Nonsense, Cystic Fibrosis, RNA, Transfer. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ANR, AFM-Téléthon, Association Vaincre la Mucoviscidose.
Abstract (Originalsprache)
Nonsense mutations account for 12 % of cystic fibrosis (CF) cases. The presence of a premature termination codon (PTC) leads to gene inactivation, which can be countered by the use of drugs stimulating PTC readthrough, restoring production of the full-length protein. We recently identified a new readthrough inducer, TLN468, more efficient than gentamicin. We measured the readthrough induced by these two drugs with different cystic fibrosis transmembrane conductance regulator (CFTR) PTCs. We then determined the amino acids inserted at the S1196X, G542X, W846X and E1417X PTCs of CFTR during readthrough induced by gentamicin or TLN468. TLN468 significantly promoted the incorporation of one specific amino acid, whereas gentamicin did not greatly modify the proportions of the various amino acids incorporated relative to basal conditions. The function of the engineered missense CFTR channels corresponding to these four PTCs was assessed with and without potentiator. For the recoded CFTR, except for E1417Q and G542W, the PTC readthrough induced by TLN468 allowed the expression of CFTR variants that were correctly processed and had significant activity that was enhanced by CFTR modulators. These results suggest that it would be relevant to assess the therapeutic benefit of TLN468 PTC suppression in combination with CFTR modulators in preclinical assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, Gif-sur-Yvette, 91198, France.
- CNRS, INSERM, Institut Necker Enfants Malades-INEM, Université Paris Cité, Paris, F-75015, France.
- CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, Gif-sur-Yvette, 91198, France; Sorbonne Université, 4 Place Jussieu, Paris, 75005, France.
- CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, Gif-sur-Yvette, 91198, France. Electronic address: olivier.namy@i2bc.paris-saclay.fr.
Förderung
- ANR
- AFM-Téléthon
- Association Vaincre la Mucoviscidose
Zitieren
APA
Karri, S., Cornu, D., Serot, C., Biri, L., Hatton, A., Dréanot, E., Rullaud, C., Pranke, I., Sermet-Gaudelus, I., Hinzpeter, A., Bidou, L., & Namy, O. (2024). TLN468 changes the pattern of tRNA used to read through premature termination codons in CFTR. Journal of Cystic Fibrosis, 23(6), 1185-1194. https://doi.org/10.1016/j.jcf.2024.07.017
Vancouver
Karri S, Cornu D, Serot C, Biri L, Hatton A, Dréanot E, et al. TLN468 changes the pattern of tRNA used to read through premature termination codons in CFTR. Journal of Cystic Fibrosis. 2024;23(6):1185-1194. doi:10.1016/j.jcf.2024.07.017
BibTeX
@article{Karri2024,
author = {Karri, Sabrina and Cornu, David and Serot, Claudia and Biri, Lynda and Hatton, Aurélie and Dréanot, Elise and Rullaud, Camille and Pranke, Iwona and Sermet-Gaudelus, Isabelle and Hinzpeter, Alexandre and Bidou, Laure and Namy, Olivier},
title = {TLN468 changes the pattern of tRNA used to read through premature termination codons in CFTR},
journal = {Journal of Cystic Fibrosis},
year = {2024},
volume = {23},
number = {6},
pages = {1185--1194},
doi = {10.1016/j.jcf.2024.07.017}
}
EUVIMED